NCT04238819: A Study of Abemaciclib (LY2835219) in Combination With Other Anti-Cancer Treatments in Children and Young Adult Participants With Solid Tumors, Including Neuroblastoma

Sponsor: Eli Lilly and Company. Phase: PHASE1. Conditions: Relapsed Solid Tumor, Refractory Solid Tumor